scholarly journals The atypical pattern of cell death in B16F10 melanoma cells treated with TNP-470

Author(s):  
Marcin Okrój ◽  
Dorota Stawikowska ◽  
Ewa Słomińska ◽  
Andrzej Myśliwski ◽  
Jacek Bigda

AbstractTNP-470 is an acknowledged anti-angiogenic factor, and was studied clinically as an anti-cancer drug. We previously reported on an additional property of this molecule: the intracellular generation of reactive oxygen species in B16F10 melanoma cells. We showed that a massive generation of ROS occurred in the first few hours after treatment with TNP-470 and that this event was critical to subsequent cell death. In this study, we analyzed the process of cell death and noticed an atypical pattern of death markers. Some of these, such as DNA fragmentation or condensation of chromatin, were characteristic for programmed cell death, while others (the lack of phosphatidylserine flip-flop but permeability to propidium iodide, the maintenance of adhesion to the substratum, no change in mitochondrial transmembrane potential, no effect of the panspecific caspase inhibitor) rather suggested a necrotic outcome. We concluded that TNP-470 induced at least some pathways of programmed cell death. However, increasing damage to critical cell functions appears to cause a rapid switch into the necrotic mode. Our data is similar to that in other reports describing the action of ROS-generating agents. We hypothesize that this rapid programmed cell death/necrosis switch is a common scenario following free radical stress.

Cancers ◽  
2021 ◽  
Vol 13 (20) ◽  
pp. 5190
Author(s):  
Fumio Sakane ◽  
Fumi Hoshino ◽  
Masayuki Ebina ◽  
Hiromichi Sakai ◽  
Daisuke Takahashi

Diacylglycerol (DG) kinase (DGK) phosphorylates DG to generate phosphatidic acid (PA). The α isozyme is activated by Ca2+ through its EF-hand motifs and tyrosine phosphorylation. DGKα is highly expressed in several refractory cancer cells including melanoma, hepatocellular carcinoma, and glioblastoma cells. In melanoma cells, DGKα is an antiapoptotic factor that activates nuclear factor-κB (NF-κB) through the atypical protein kinase C (PKC) ζ-mediated phosphorylation of NF-κB. DGKα acts as an enhancer of proliferative activity through the Raf–MEK–ERK pathway and consequently exacerbates hepatocellular carcinoma progression. In glioblastoma and melanoma cells, DGKα attenuates apoptosis by enhancing the phosphodiesterase (PDE)-4A1–mammalian target of the rapamycin pathway. As PA activates PKCζ, Raf, and PDE, it is likely that PA generated by DGKα plays an important role in the proliferation/antiapoptosis of cancer cells. In addition to cancer cells, DGKα is highly abundant in T cells and induces a nonresponsive state (anergy), which represents the main mechanism by which advanced cancers escape immune action. In T cells, DGKα attenuates the activity of Ras-guanyl nucleotide-releasing protein, which is activated by DG and avoids anergy through DG consumption. Therefore, a DGKα-specific inhibitor is expected to be a dual effective anticancer treatment that inhibits cancer cell proliferation and simultaneously enhances T cell functions. Moreover, the inhibition of DGKα synergistically enhances the anticancer effects of programmed cell death-1/programmed cell death ligand 1 blockade. Taken together, DGKα inhibition provides a promising new treatment strategy for refractory cancers.


2017 ◽  
Vol 46 (1) ◽  
pp. 34-38
Author(s):  
Hyang Suk Kim ◽  
Ji Min Cheon ◽  
Da Hye Kwon ◽  
Eun Ok Choi ◽  
Min Ju Kim ◽  
...  

1988 ◽  
Vol 6 (2) ◽  
pp. 153-169 ◽  
Author(s):  
E. Barberá-Guillem ◽  
M. L. Cañavate ◽  
I. Lopez De Tejada ◽  
F. Vidal-Vanaclocha

2008 ◽  
Vol 25 (6) ◽  
pp. 1463-1466 ◽  
Author(s):  
Eun-Suk Hong ◽  
Duc Thi Minh Nguyen ◽  
Dung Hoang Nguyen ◽  
Eun-Ki Kim

2018 ◽  
Vol 39 (11) ◽  
pp. 1254-1258
Author(s):  
Ha Na Ko ◽  
Jung Eun Kim ◽  
Yeon Jeong Jo ◽  
Seung Hyun Hong ◽  
Da Wun Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document